HCA Healthcare (HCA) Gets a Buy from KeyBanc
KeyBanc analyst Matthew Gillmor CFA maintained a Buy rating on HCA Healthcare today and set a price target of $550.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gillmor CFA covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, BrightSpring Health Services, Inc., and Acadia Healthcare. According to TipRanks, Gillmor CFA has an average return of -6.1% and a 41.18% success rate on recommended stocks.
In addition to KeyBanc, HCA Healthcare also received a Buy from Barclays’s Andrew Mok CFA in a report issued today. However, yesterday, Bernstein maintained a Hold rating on HCA Healthcare (NYSE: HCA).
Based on HCA Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $19.16 billion and a net profit of $1.67 billion. In comparison, last year the company earned a revenue of $17.49 billion and had a net profit of $1.27 billion
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Most recently, in November 2025, Michael R McAlevey, the EVP & Chief Legal & Admin Off of HCA sold 3,892.00 shares for a total of $1,843,990.68.
Read More on HCA:
